Market Movers

Elevance Health, Inc.’s Stock Price Takes a Dip at $430.77, Recording a 3.06% Decrease: Time to Buy?

By October 19, 2024 No Comments

Elevance Health, Inc. (ELV)

430.77 USD -13.58 (-3.06%) Volume: 3.32M

Elevance Health, Inc.’s stock price is currently standing at 430.77 USD, experiencing a dip of 3.06% this trading session with a trading volume of 3.32M. The stock has seen a downward trend YTD, with a percentage change of -8.65%, indicating a challenging market environment for ELV.


Latest developments on Elevance Health, Inc.

Elevance Health, Inc. (ELV) faced a turbulent period as it reported lower-than-expected earnings, attributing the profit decline to persistently high medical costs and ‘unprecedented’ challenges in the Medicaid sector. The company’s Q3 earnings call highlighted the impact of Medicaid redeterminations on its financial performance, leading to a soft annual outlook and a subsequent drop in stock price. Despite revenue growth and beating expectations, Elevance Health’s profit fell short, causing analysts to cut their forecasts and prompting a 12% plunge in stock value. The company’s struggles with rising medical expenses post-COVID-19 policies have led to a cautious market sentiment, reflected in a 2.5% trading dip and a lowered price target by financial institutions. Despite maintaining its dividend payout, Elevance Health’s stock price remains under pressure due to ongoing Medicaid challenges and lower earnings projections.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars